Molecular mechanism of FXa inhibition by Alboserpin, the major salivary gland anticoagulant from the mosquito and yellow fever vector Aedes albopictus, has been characterized. cDNA of Alboserpin predicts a 45-kDa protein that belongs to the serpin family of protease inhibitors. Recombinant Alboserpin displays stoichiometric, competitive, reversible and tight binding to FXa (pM range). Binding is highly specific and is not detectable for FX, catalytic siteblocked FXa, thrombin and 12 other enzymes. Alboserpin displays highaffinity binding to heparin (K D~2 0 nM), but no change in FXa inhibition was observed in the presence of the cofactor, implying that bridging mechanisms did not take place. Notably, alboserpin was also found to interact with phosphatidylcholine (PC) and phosphatidylethanolamine (PE) but not with phosphatidylserine (PS). To acquire a blood meal, haematophagous arthropods usually break the host's skin stratum corneum (1-2). As a result, wounded tissues and injured blood vessels trigger the host hemostatic process which is a complex and redundant, interlinked biological system consisting of platelet aggregation, blood clotting, and vasoconstriction (3) (4) (5) . The clotting cascade can be activated by the intrinsic or extrinsic pathways, both converging to the activation of factor X (FX) to FXa, which converts prothrombin to thrombin; the latter cleaves fibrinogen to produce fibrin (6) . FXa also plays a pivotal role in inflammation through activation of protease-activated receptors (7) . In order to counteract host response to injury, salivary glands (SGs) of blood-sucking arthropods express a number of inhibitors of blood coagulation, platelet aggregation, host immunity, inflammation, angiogenesis, neutrophil function, wound healing and vasodilation (1, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17, 21) . Notably, the only serine protease inhibitor (serpin) described so far and found to target FXa was identified in the SG of the mosquito Aedes aegypti (22) .
Serpins are a large and growing superfamily of structurally homologous yet functionally diverse proteins. Serpins have been identified in species of all kingdoms. These protease inhibitors act to control proteolytic activity in a myriad of contexts including coagulation, fibrinolysis, and complement activation. They can also be found in the intracellular compartment and perform biologic functions that do not necessarily require their protease inhibitory function. Approximately 500 serpins are currently known, consisting of between 350 and 400 amino acids with molecular weights ranging from 40 to 55 kDa (23) (24) (25) . In this study, we describe the main anticoagulant from Aedes albopictus SGs. We provide experimental evidence indicating that the molecule responsible for this salivary activity belongs to the serpin superfamily (hereafter named Alboserpin). We show that recombinant Alboserpin is a highly specific, tight inhibitor of FXa. Both recombinant Alboserpin and Ae. albopictus saliva do not bind to FX or active site-blocked DEGRFXa. Moreover, Alboserpin binds heparin; notably, it also interacts with phosphatidylcholine (PC), and phosphatidylethanolamine (PE) but not with phosphatidylserine (PS). In addition, it displays potent antithrombotic properties in vivo.
Methods
Unless otherwise indicated, the protocols followed standard procedures (26) and all experiments were performed at room temperature (25 ± 1ºC). All water used was of 18 MΩ quality, produced by a MilliQ apparatus (Millipore, Bedford, MA). Heparin (low molecular weight, 4-6 kDa average) from porcine intestinal mucosa was purchase from Sigma Chemical Co. (St. Louis, MO). Egg L--PC and brain L--PS were obtained from Avanti Polar Lipids (Birmingham, AL). Phosphatidylethanolamine (PE) from bovine brain was purchased from Sigma Chemical Co.
Phylogenetic analysis of the serpin family BLASTP analysis was performed with Alboserpin (GI: 56417456) against the nonredundant database, and all bloodfeeding insect sequences were retrieved. Sequences were cleaned up to obtain a nonredundant set (proteins with >95% identity in the core domain were treated as identical) and aligned with ClustalX (27-28). Alignments were manually checked, adjusted, and trimmed to include the conserved serpin core. Phylogenetic analysis was performed using Neighbor-joining analysis (29) . Gapped positions were treated by pairwise deletion. Poisson correction was used as a substitution model to determine pairwise distances. Confidence was determined using bootstrap analysis (10,000 replicates) with 346 informative sites.
Modeling and electrostatic surface calculations
The structure of Alboserpin was modeled using the automatic modeling mode in SWISS-MODEL (30) . Alboserpin coordinates were loaded on Pymol and the electrostatic surface calculated using the APBS tools. The template structure was the antithrombin-S195A factor Xapentasaccharide complex (2GD4). Secondary structure was obtained based on alboserpin model. Ae. albopicitus collection of saliva and SG dissection Samples of saliva from female Ae. albopictus mosquitoes were collected by oilinduced salivation. After saliva collection, the sample was spun down at 14000×g in a bench-top centrifuge and the lower phase, containing the saliva, was transferred to a clean Eppendorf tube. SGs were dissected as indicated (31) . The protein concentration from the collected saliva and SG extracts was estimated spectrophotometrically in a ND1000 (NanoDrop Technologies, Wilmington, DE).
Expression of Alboserpin in

Escherichia coli
For bacterial expression of recombinant Alboserpin, a synthetic gene was designed coding for the mature protein, which also contains NdeI and XhoI restriction sites. The synthetic Alboserpin gene was subcloned into pET-17b (Biobasic Inc., Markham, Ontario, Canada) for expression in E. coli (BL21pLYS) cells. Recombinant protein production and inclusion body preparation were carried out as indicated (9) . The inclusion bodies were solubilized in 20 mM Tris-HCl, pH 7.4, 6 M guanidinium hydrochloride, 15 mM dithiothreitol, 1 mM EDTA. The solubilized material was diluted in 4 liters of 50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.2 mM GSSG, 1 mM GSH, and 200 mM arginine monohydrochloride and incubated overnight. Refolded Alboserpin was concentrated and purified as indicated (9) . The purified recombinant protein was submitted to automated Edman degradation for N-terminal sequencing. Concentration of purified Alboserpin (corrected for ε 280nm = 44410) (calculated using software from DNAStar Inc., Madison, WI) was estimated by its absorbance at 280 nm using a NanoDrop ND1000 spectrophotometer (NanoDrop Technologies).
Anticoagulant assays
Anticlotting measurements were performed by either measuring the recalcification time as described before (32) Affinity chromatography on a heparin-sepharose column Two μM of FXa was incubated for 2 minutes in the absence or presence of Alboserpin (5 M) in 50 mM Tris-HCl, pH 7.4, buffer containing 5 mM CaCl 2 . The sample (0.5 ml) was applied at 0.5 mL/minute on a 1 mL HiTrap heparinsepharose (GE Healthcare, Piscataway, NJ) column pre-equilibrated with the same buffer. The column was washed with 8 mL followed by elution with a 30 mL gradient of 0-1.0 M NaCl prepared in the same buffer. Fractions (0.5 ml) were collected, and their activity toward S2222 was determined as described above.
Prothrombinase assembly
Activation of prothrombin by human FXa was performed in TBS-Ca 2+ (20 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl 2 , 0.3% (w/v) BSA, pH 7.5), using a discontinuous assay. FXa (10 pM; final concentrations are given) was incubated with Alboserpin (0-500 pM) for 20 minutes at room temperature. Human FVa (1 nM) and PC/PS (10 μM) were added and incubated for 5 minutes. Reactions were initiated by addition of human prothrombin (1.4 μM). Aliquots of 25 μL were removed every minute into microplate wells containing 50 μL of TBS-EDTA (20 mM Tris-HCl, 150 mM NaCl, 20 mM EDTA, 0.1% BSA, pH 7.5) to stop reactions. After addition of 25 μL of S2238 (312.5 μM), absorbance at 405 nm was recorded at 37ºC for 15 min at 11-second intervals using a Thermomax microplate reader (Molecular Devices). Initial velocities (mOD/minute) obtained were used to calculate the amount of thrombin formed, using a standard curve (33) . Absence of one of the components in the prothrombinase showed no thrombin formation.
Surface plasmon resonance (SPR)
Binding of recombinant Alboserpin to FXa, FX, and FXa-DEGR (active site-blocked factor Xa containing the fluorescent inhibitor Dansyl-EGRck) was analyzed at 25°C by SPR spectrometry using a BIAcore T100 instrument (BIAcore AB, Uppsala, Sweden) as described (34) . Factors X, Xa, and Xa-DEGR (30 µg/mL) were covalently immobilized on the surface of a CM5 sensor chip using the amine coupling kit supplied by BIAcore at a flow rate of 10 µL/minute-aiming to reach 1500RU in 10 mM acetate buffer pH 4.8-resulting in a final immobilization of 1470.8 RU for FXa, 1764.4 RU for FX, and 1807 RU for FXa-DEGR. Blank flow cells were used to subtract the buffer effect on the sensograms. For kinetic experiments, recombinant Alboserpin in concentrations ranging from 0.04-25 nM was run for 120 seconds at 30 μL/minute in HBS-P buffer (10 mM HEPES, 150 mM NaCl, 0.005% surfactant P20, pH 7.4). The Alboserpin-coagulation factor complex dissociation was monitored for 1800 seconds, and the active cell was regenerated with 3-second pulse (50 µL/min) of 10 mM glycine-HCl, pH 1.5. Kinetic experiments were performed in triplicate on different days. The same experimental design was utilized for kinetic analysis of bacterially expressed Alboserpin. BIAcore T100 evaluation software was used for kinetic evaluation, and sensograms were fitted using the 1:1 binding model (Langmuir binding model). Alternatively, an experiment was designed to test the presence of salivary Alboserpin in the mosquito's saliva. A new sensor chip was used so as to have the FX, Xa, and FXa-DEGR on the same sensor chip. The flow cell 1 was used as a blank to subtract the buffer effect on the sensograms. The immobilization procedure was the same as described above. Four different concentrations of Ae. albopictus saliva (15, 25, 50 , and 90 g/mL in HBS-P) were manually injected over the four flow cells in the sensor chip for 90 seconds at a flow rate of 20 µL/minute. The complex dissociation was monitored for 500 seconds and the sensor surface regenerated by a pulse of 5 seconds of 10 mM glycine-HCl, pH 1.5, at 40 µL/minute. These experiments were carried out in duplicate.
Binding of recombinant Alboserpin to heparin was carried out by SPR using a BIAcore 3000 instrument. Heparin (4-6 kDa average MW) was biotinylated at the reducing end and injected over a SA-sensor chip (GE Healthcare) in HBS-P (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% P20 surfactant) at a flow rate of 10 μL/minute for 2 minutes. The resulting immobilization level obtained was 230.6 RU. The kinetics assay was performed at 25ºC in HBS-P. Alboserpin concentrations ranging from 3.9 to 62.25 nM were allowed to interact to immobilized heparin for 180 seconds at 30 µL/minute. Alboserpin-heparin complex dissociations were monitored for 600 seconds and the sensor regenerated with 1-minute injection of 2.5 M NaCl at 30 µL/minute. Kinetic parameters (k on , k off , and K D ) were determined by global fitting of the sensograms using the 1:1 Langmuir binding model in the BIAcore Evaluation 3.1 software.
Isothermal titration calorimetry
Calorimetric assays for measuring FXa binding to Alboserpin were performed using a VPITC microcalorimeter (Microcal, Northampton, MA) at 30°C. Titration experiments were performed by successive injections of 10 μL each of 17 µM of FXa into the sample cell containing 2 µM of Alboserpin. Prior to the run, the proteins were dialyzed against 50 mM Tris-HCl, 0.15 M NaCl, pH 7.4, 5 mM CaCl 2 for binding experiments. All solutions were degassed under vacuum for 5 minutes before use.
The calorimetric enthalpy (ΔH cal ) for each injection was calculated, and binding isotherms were fitted according to a model for a single binding site by nonlinear squares analysis using Microcal Origin software. The enthalpy change (ΔH), and stoichiometry (n) were determined according to equation 2:
where Q is the total heat content of the solution contained in the cell volume (Vo) at fractional saturation θ, ΔH is the molar heat of ligand binding, n is the number of sites, and Mt is the bulk concentration of macromolecule in Vo. The binding constant, Ka, is described as:
where [X] is the free concentration of ligand.
Binding of Alboserpin to FXa by sizeexclusion chromatography
Analysis of Alboserpin-FXa complex formation was carried out using a Superdex 75 PC 3.2/30 column (3.2 × 300 mm; GE Healthcare), 2.4-mL bed volume, assembled in Akta Purifier equipment (Amersham Pharmacia Biotech). The column optimal separation range is 300-70000 Da, with an exclusion limit of 100,000 Da. The column was equilibrated in HEPES-buffered saline, pH 7.4 (HBS) at 40 µL/minute. For the experiment runs, recombinant Alboserpin and FXa were loaded independently on the column. For the Alboserpin-FXa complex, equimolar concentrations of both proteins were incubated in HBS at room temperature.
After 30 minutes of incubation, the mixture was loaded on the column, and the proteinprotein complex was monitored at 280 nm.
Phospholipid vesicle formation and protein binding
Large unilamellar vesicles were formed by drying the lipids in a chloroform solution under a stream of nitrogen in a glass vial, then resuspended in 20 mM Tris HCl, pH 7.4, vortexed and extruded using a LiposoFast (Avestin Inc., Ottawa, Ontario, Canada) extrusion device. Extrusion was performed through two (stacked) polycarbonated filters (19-mm diameter) of 0.1 µm pore size (Whatman, Clifton, NJ). The final concentration of the vesicle suspensions was 1 mg/mL, and nitrogen was bubbled through the mixture during preparation. Binding was measured at various salt concentrations by diluting the vesicle suspension in TBS containing the appropriate concentration of NaCl and 3 Μ Alboserpin in a final volume of 50 μL. A second set of competition experiments was carried out where Alboserpin and phospholipids were incubated in the presence of 30 µg/mL of heparin or 10 µM of annexin V. The mixtures were incubated at room temperature for 30 minutes and centrifuged at 100,000×g for 30 minutes. The supernatant was removed and the pellet resuspended in 40 μL of 1× LDS loading buffer supplemented with 1× NuPAGE reducing agent. Both the pellet and supernatant fractions were analyzed by SDS−PAGE, and the fraction of bound protein was determined by densitometry of Coomassie blue-stained gels using ImageJ software (public domain, open source; NIH).
Animals and tail bleeding assay; ex vivo PT and aPTT assays
Female C57BL/6 mice (6-10 weeks old) were purchased from Charles River Laboratories (Wilmington, MA). Mice were maintained at an American Association of Laboratory Animal Care-accredited facility at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. All experiments with mice were evaluated and approved by the NIAID Animal Care and Use Committee of the NIH (Rockville, MD). For the tail-vein bleeding assay, mice were injected intravenously with phosphate-buffered saline (PBS) or two doses of Alboserpin (10 and 100 µg/kg) in a 100 µL volume. After 30 minutes, mice were anesthetized and placed on a warming pad. A transverse incision was performed using a scalpel over a lateral vein at a position where the diameter of the tail is 2.5 mm. The tails were left hanging over the edge of the bench and immersed in a 12 × 75 mm tube containing 4 mL saline buffer for 30 minutes. The tubes were gently rotated from time to time to prevent the shed blood from obscuring the incision. Although only a mild bleeding was expected to occur in the assay, mice were observed for the next 6 hours for signs of delayed bleeding. The samples were properly diluted and the absorbance determined at 540 nm to estimate hemoglobin content. Results represent the mean ± SEM of three animals per group, and the assay was repeated twice.
A second group of mice identically treated with Alboserpin or PBS was used for ex vivo aPTT and PT assays. Briefly, 1 hour after Alboserpin or PBS administration, blood was collected by cardiac puncture in 3.8% trisodium citrate (9:1, v/v). Plateletpoor plasma was obtained by centrifugation at 2000×g for 15 minutes. aPTT and PT assays were carried out as described above.
FeCl 3 -induced artery thrombosis
Mice were anesthetized with intramuscular xylazin (16 mg/kg) followed by ketamine (100 mg/kg). The right common carotid artery was isolated through a midline cervical incision, and the blood flow was continuously monitored using a 0.5VB Doppler flow probe coupled to a TS420 flow meter (Transonic Systems, Ithaca, NY) as described previously (35) . Alboserpin (at 50, 100, or 200 µg/kg) or vehicle was infused into the tail vein 15 minutes before injury. Thrombus formation was induced by applying a piece of filter paper (1 × 2 mm) saturated with 7.5% FeCl 3 solution on the adventitial surface of the artery for 3 minutes. After exposure, the filter paper was removed, and the vessel was washed with sterile normal saline. Carotid blood flow was continuously monitored for 60 minutes or until complete occlusion (0 flow for at least 10 seconds) occurred.
Serine protease inhibition assays
All assays were performed at 30ºC in triplicate. Protein (300 nM) was preincubated, with each enzyme tested for 10 minutes before the addition of the corresponding substrate as described (36) .
Statistical analysis
Statistical differences among the groups were analyzed by analysis of variance (ANOVA) using Tukey as a multiple comparison post-test. A P value of 0.05 or less was considered statistically significant.
Results and Discussion
The sialotranscriptome of female Ae. albopictus SG (37) revealed a cluster of sequences coding for a putative serpin protein similar to the Ae. aegypti FXadirected anticoagulant factor (22) . The Alboserpin cDNA has 1,257 nucleotides, coding for a protein of 418 amino acids, including a signal peptide of 19 amino acids (gi:56417456). The mature protein has a calculated MW of 45,986.97 Da, with a pI of 9.21.
CALVO -8
Alboserpin is an atypical serpin Salivary FXa inhibitors have been classified as Kunitz-type, antistasin family, ascaristype protease inhibitor, and SALP family (17) . Sequence analysis of Alboserpin shows high sequence similarities to several other serpins, including PAI-2, antithrombin, and PCI. A CLUSTAL alignment of Alboseprin and other relevant serpins is presented in Figure 1 . A comparison of the reactive site loop with Alboserpin and known serpin proteins illustrates that while there is remarkable conservation in amino acid sequences, there is also considerable divergence. For example, the reactive site loop in Alboserpin appears to be truncated in comparison with other serpins. The predicted P1 for Alboserpin aligns as an arginine that would be expected for FXaspecific serine protease inhibitor. Furthermore, P17 within the hinge region is typically a glutamic acid residue, while in Alboserpin it is a histidine residue. This P17 has been identified as glutamic acid for 39 serpins analyzed (23) (24) (25) . The hinge region of serpins is proposed to be essential for protease inhibition (mousetrap mechanism) by promoting a conformational change that allows a tight interaction with the active site of serine proteases followed by cleavage of the P1-P1' peptide bond of the serpin RCL (23) (24) (25) . This forms an acyl-intermediate complex in which the bond is cleaved and the P1 residue becomes covalently linked to the enzyme. This leads to a large conformational change in which the RCL inserts into the center of β-sheet A, causing the tethered proteinase to be dragged to the opposite end of the protein and inactivated by conformational deformation and irreversible binding. Other serpins have less typical mechanisms (23) (24) (25) . Thus, Alboserpin shares primary amino acid sequence in common with typical serpins, including the appropriate spacing of domains, but significant divergence is evident and makes it a unique protein.
Alboserpin and phylogeny Figure 2A shows BLASTP analysis using the FXa inhibitor from Ae. albopictus retrieved serpins from several blood-feeding insects that included the tsetse fly Glossina morsitans morsitans, the sand fly Lutzomyia longipalpis, the cat flea Ctenocephalides felis, and the mosquitoes Anopheles gambiae, Ae. aegypti, and Ae. albopictus. The recently sequenced genomes of An. gambiae and Ae. aegypti contributed the bulk of the serpins retrieved. Most of these grouped into well supported clades, indicating that they are orthologs and limited to the head and fat bodies, which suggest that they perform housekeeping functions conserved in the ancestor to all Culicidae. The proteins from the Aedes genus that has a confirmed localization to the SG group into a well supported clade to the exclusion of any Anopheline sequences. BLASTP analyses of the genome of An. gambiae using any of these sequences do not retrieve other serpins, which suggests that no orthologs exists for these proteins in Anopheles. The closest homologs are serpin 14 from fat bodies. This suggests that a gene duplication event in SG led to the evolution of a new class of SG-derived serpins in Aedes sp.
Charges and model
The structure of Alboserpin was modeled using the fully automated structure homology-modeling server. The model coordinates obtained were based on antithrombin-S195A factor Xapentasaccharide complex (2GD4). Modeled Alboserpin shows a typical three-dimensional structure of native inhibitory serpin with its RCL completely exposed ( Figure 2B ). The electrostatic surface generated using the Adaptive Poisson Bolzmann Solver (APBS)shows a highly positively charged region similar to the one found in the antithrombin-S195A factor Xapentasaccharide complex ( Figure 2C ). This region might be the heparin binding site in Alboserpin. Further structural study is necessary to address this question.
Anticlotting activity in saliva and SGs of Ae. albopictus
In an attempt to characterize the anticoagulant activity of Alboserpin, the corresponding cDNA was cloned in a Pet17b expression vector and expression induced by IPTG. Alboserpin was purified in a Mono-Q ion exchange column (not shown) followed by a last step in molecular sieving chromatography. It was eluted at 10 ml which corresponds to a protein of ~45 kDa ( Figure 3A ). This finding was consistent with the predicted molecular weight for Alboserpin and is indicative of high purity of the preparation as confirmed by SDS/PAGE ( Figure 3A, inset) . Recombinant Alboserpin produced in E. coli was tested in coagulation assays. Figure 3B shows that Alboserpin prolongs both PT and aPTT, while Figure 3C shows that it also blocks prothrombinase assembly in a dosedependent manner, consistent with FXadirected anticoagulant. Ae. albopictus SGs also increase the recalcification time ( Figure  3D ) and prolong both PT and aPTT ( Figure  3E ). In addition, SPR experiments demonstrated unambiguously that saliva displays FXa-binding properties ( Figure 3F ). Table 1 shows that incubation of Alboserpin with a series of enzymes does not affect their catalytic activities, indicating that Alboserpin is a highly specific FXa inhibitor.
Specifiticy of Alboserpin
Alboserpin is a tight inhibitor of FXa
Experiments revealed that when FXa was added to the reaction buffer containing Alboserpin and chromogenic substrate, the progress curve displayed a downward concavity ( Figure 4A, curve b and c) . These results resemble slow-binding kinetics, as seen with many peptidic inhibitors of serine proteinases when small chromogenic or fluorogenic substrates are used to kinetically characterize the interaction. However, appropriate kinetics studies are needed to further address this question. In addition, Alboserpin significantly inhibits FXa at concentrations similar to that of the enzyme ( Figure 4B ), indicating that Alboserpin is also a tight-binding inhibitor. Conventional Michaelis−Menten kinetics do not apply to the study of tight-binding inhibitors, because they assume that the free inhibitor concentration is equal to the total inhibitor concentration, a reasonable approximation when the enzyme used is at a much lower concentration than the inhibitor. Therefore, Morrison's equation for tight-binding inhibition (38) was used as described (19) to obtain apparent dissociation constants for Alboserpin. In these experiments, 25 pM of FXa was allowed to interact with increasing inhibitor concentrations (0-525 pM) for 30 minutes in the presence of varying concentrations of substrate (100-500 µM) before product rate formation for the following 30 minutes was recorded (not shown). Resulting steady-state rates were fit by nonlinear regression to Equation 1 for several substrate concentrations as described (19) . When the Ki* was plotted against the substrate concentration, a linear regression line (r 68.2 ± 5.4 pM, which is the Ki value for the binding of Alboserpin to FXa ( Figure 4C ).
Kinetics and stoichiometry of Alboserpin-FXa interactions
To investigate binding kinetics of Alboserpin-FXa interactions, SPR experiments were performed. Typical sensograms are shown in Figure 5A . Best fit was attained using a 1:1 model. Using this model, a k on of 1.005 × 10 were obtained .The fast k on for Alboserpin-FXa interaction determined by SPR suggest that enzyme activity is blocked very shortly after binding to the serpin. Accordingly, it is plausible that interactions of FXa with Alboserpin can be better described as fast when physiological macromolecules (FXa) instead of small chromogenic substrates (S2222), are used to determine the kinetics of the interaction involving enzyme and inhibitor. Similar findings have been reported before for tick salivary FVIIa/TF inhibitor, Ixolaris (20) . While the remarkably low k off makes it inaccurate to calculate the K D , it was estimated at 26.85 pM, which is in reasonable agreement with the affinity estimated by the Morrison equation ( Figure  4C) . Notably, covalent binding of Alboserpin to FXa did not take place, as acidic conditions (glycine, pH 1.5) dissociates Alboserpin from FXa immobilized in the sensor chip in contrast to typical serpins. In this respect, Alboserpin more likely behaves as a Kunitz-type inhibitor, which binding to serine proteases are typically reversible (39) . No binding was observed for FX or DEGR-FXa ( Figure 5B) , which is an indication of the catalytic site dependence for binding; however, interaction of the serpin with FXa exosite cannot be excluded (40) (41) .
Binding of Alboserpin to FXa was measured by isothermal titration calorimetry (ITC) with the results shown in Figure 5C . Figure 5C ). Binding of Alboserpin to FXa was also confirmed by identification of complex formation that eluted at a MW compatible with 1:1 interaction, as estimated by gel-filtration chromatography ( Figure  5D ). Figure 5E demonstrates that alboserpin-FXa complex formation dissociates when the sample is warmed at 70 o C for 7 min, indicating that complex is reversible in contrast to typical serpins. This result is consistent with reversible interaction also demonstrated by SPR. While Alboserpin-FXa complex formation is kinetically reversible, it is conceivable that this tight interaction results in perhaps a functionally irreversible binding in nature. Finally, saliva was found to interact with FXa but not DEGR-FXa, consistent with presence of Alboserpin in the native secretion ( Figure 5F ).
Alboserpin interacts with heparin
Heparin accelerates the rate of vertebrate plasma antithrombin (AT) inhibition of FXa by three to four orders of magnitude (40) . In fact, AT that normally regulates the proteolytic activity of FXa is a weak inhibitor of coagulation proteinases unless it binds heparin-like glycosaminoglycans. Heparin binding to both protease and serpin enhances the rate of encounter complex formation between the two proteins (bridging effects) (42) . To verify whether Alboserpin binds to heparin, SPR experiments were performed as described in Methods. Figure 6A ). In addition, Figure 6B demonstrates that FXa binds to heparin-sepharose column and is eluted with a NaCl gradient. Next, we studied the effects of heparin in the inhibition of FXa by Alboserpin. FXa (1 nM) was used to start reactions containing a mixture of S2222 and alboserpin, with and without heparin. Alboserpin was tested at low concentrations (<0.5 nM) producing partial inhibition of FXa catalytic activity in order to observe any possible effects of heparin. Figure 6C shows that progress curves for FXa inhibition by Alboserpin were the same in the absence or in the presence of heparin. The effects of heparin were also tested after incubation of FXa with Alboserpin followed by addition of S2222 to start reactions. Figure 6D demonstrates that the curves were superimposed indicating no change in the affinity. It is concluded that alboserpin belongs to the subfamily of serpins such as AT (40), heparin cofactor II (43) , protease nexin I (44), PZI (45), PAI-1(46) and PCI (47) which reportedly binds heparin and other glycosaminoglycans. However, heparin does not operate as a bridge for Alboserpin to interact with proteinases. In other words, Alboserpin interacts with FXa irrespective of the presence of cofactors (e.g. heparin). This is not surprising, taking into account the tight binding of FXa and Alboserpin which affinity is in the range of thrombin-antithrombin complex when heparin is present. It is also important to recognize that heparan sulfate-containing proteoglycans are found membraneassociated to the cell surface and can substitute for heparin. Plausibly, heparin functions as an anchor that targets Alboserpin to endothelial cells, localizing it at the site of injury where it remains bound instead of free in solution, resulting in higher effective concentration. In this context, TFPI and VEGF binding to heparin has also been demonstrated and sought to contribute to localization in endothelial cells and other GAG-bearing cells (48) (49) .
Alboserpin interacts with PC and PE, but not with PS
Among serpin family members, PCI was initially found to bind to PE, PS and PC (50). However, PCI was later demonstrated to interact with oxidized PE or oxidized PS, but not with PC (47, 51) . Therefore, binding of Alboserpin to phospholipids vesicles in solution was investigated. Alboserpin was incubated with PC, PS, PE or PC/PS for 15 minutes, followed by centrifugation at 100,000×g. Phospholipid preparation was performed under N 2 in order to avoid oxidation. The pellet and the supernatant were collected, and bound (found in the pellet) or free (found in the supernatant) Alboserpin was detected by SDS-PAGE. Figure 7A demonstrates that Alboserpin binds to PC and PE, but surprisingly not to PS. This phospholipid specificity distinguishes Alboserpin and PCI, which is a PS-binding serpin (50) . It also binds to a mixture of PC/PS (4:1), which mimics phospholipid composition of activated platelets. When salt concentration was increased above 0.2 M NaCl, Alboserpin interaction with PC/PS was gradually lost (Figure 7B for gel; Figure 7C for quantification). In addition, as a control, salivary protein (AeDL1) also expressed in E. coli did not bind to phospholipids ( Figure  7B ). It is important to recognize that high salt concentrations may affect alboserpin binding to vesicles not only through electrostatic interference, but also by affecting vesicle structure. While we cannot exclude the later possibility, our most relevant finding is that Alboserpin binds phospholipids in solution, at physiologic ionic strength. Annexin V, a protein that binds PS in the presence of Ca 2+ , but PC in its absence (52) was used to investigate whether it can compete with Alboserpin for PC/PS binding. Experiments performed in the absence of Ca 2+ demonstrate that annexin V prevents interaction of Alboserpin to PC/PS ( Figure 7D ) suggesting competition for the same binding site, i.e., PC. In addition, incubation of Alboserpin with heparin completely abolished its interaction with PC/PS vesicles in solution, suggesting that the heparin-binding site of Alboserpin is also required for phospholipid binding ( Figure 7E ). It is plausible that PC and PE, but not PS, works as an anchor that targets the inhibitor to cells at sites of injury, or which have been activated or present at sites of inflammation. For example, PE in addition to PS, is the major phospholipid component (nearly 40%) of the outer leaflet of activated platelet membrane; accordingly, PE conceivably targets Alboserpin to sites of platelet activation. Studies have also demonstrated that PE enhances the PSmediated sensitivity of factor VIIa-tissue factor activity (53) and induces high affinity binding sites for factor VIII on surfaces containing PS (54) . Moreover, PE has been reported in tumor cell membranes (55) , and is known to regulate the activation of blood coagulation by enhancing APC inhibition by PCI (50) (51) . It is possible that occupation of these sites by Alboserpin interferes with the inhibitory function of PCI towards APC, which displays particularly important anticoagulant and anti-inflammatory activities in vivo (7, 56) . In addition, PC in its oxidized form is found in atherosclerotic lesions, apoptotic cells, and oxidized LDL and stimulate endothelial cells to produce inflammatory cytokines, leukocyte chemoattractants, and coagulation factors (57) (58) . The remarkable mechanism of action of Alboserpin-which concentrates and localizes the inhibitor at sites of injury or cell activation-suggests that it has evolved to remain bound at sites of inflammation where the concentrations of PE or PC are presumably very high. It is also clear that the phospholipid specificity of Alboserpin is unique among family members of the serpin family described so far in the sense that, in contrast to PCI, it does not recognize PS but interacts with PC. On the other hand, a lipocalin from Rhodnius prolixus binds to PS but not other phospholipids and affect multimolecular coagulation complex formation (59) . These molecular adaptations are notable examples of how evolutionary pressure has dictated the function of salivary components from bloodsucking arthropods.
Alboserpin displays antithrombotic and anticoagulant activity in vivo
To demonstrate that the anticoagulant effects of alboserpin translate into inhibition of thrombus formation, the inhibitor was injected in mice, which were then submitted to FeCl 3 -induced carotid artery injury. Application of FeCl 3 to the exterior of blood vessels causes severe endothelial damage and occlusion by platelet-rich thrombi. Times to occlusion were not significantly different between control and mice treated with 50 µg/kg of Alboserpin (16.11 ± 1.47 vs 17.0 ± 1.63 minutes) ( Figure 8A ). In contrast, mice treated with 100 and 200 µg/kg of Alboserpin were resistant to arterial occlusion, and in these cases, occlusion did not take place before 60 minutes for most animals ( Figure 8A ). These results indicate that Alboserpin inhibition of FXa effectively blocks thrombin generation at sites of vascular injury. Next, the effects of alboserpin in bleeding were estimated using the tail transection method. Figure 8B shows that Alboserpin (100 µg/kg) produces significant bleeding, as would be expected for a potent anti-FXa inhibitor. Furthermore, injection of alboserpin (100 µg/kg) in mice prolongs PT and aPTT ex-vivo (Table 2) . While the concentrations used in the experimental thrombosis model is high when compared to the amount of alboserpin injected at the site of mosquito bite, this is explained by the intensity and extension of the injury provoked by FeCl 3 . However, one may calculate the approximate concentration of the inhibitor injected by the mosquito, which causes a microinjury to the host. Accordingly, the volume of blood taken in each blood meal is ~ 4 l and ~ 50% of the salivary gland content (~1 g) is released during the bite, being Alboserpin ~ 1% of the salivary proteins (~0.01 g). This results in a concentration ~ 40 nM, which is much above Alboserpin K D for FXa. Therefore, it is evident that Alboserpin behaves as an anticoagulant and antithrombotic in vivo, which is consistent with its biologic activity characterized in vitro.
Concluding remarks
Unique binding behavior, shorter and distinct composition of the RCL, reversible interaction with the enzyme and no requirement for cofactors places Alboserpin as a useful prototype to understand structural features of FXa and serpin mechanisms of protease inhibition. Structural studies of Alboserpin will define the precise mechanism by which this molecule specifically and reversibly blocks FXa, thus preventing its role in thrombosis and inflammation (7) . Alboserpin may also be regarded as a prototype to develop anticoagulants targeting FXa, an important target of antithrombotic therapy clinically illustrated by the effectiveness of oral FXa inhibitors rivaroxaban and apixaban (60). Because E.C., J.R., J.A. and I.F. are government employees and this is a government work, the work is in the public domain in the United States. Notwithstanding any other agreements, the NIH reserves the right to provide the work to PubMedCentral for display and use by the public, and PubMedCentral may tag or modify the work consistent with its customary practices. You can establish rights outside of the U.S. subject to a government use license. 
